Surprising Results with Ultra-Low-Dose Immunotherapy: The DELII Study
In this article
Nivolumab (Opdivo) treatment at 1/12 of the standard dose (20 mg) provides superior survival to chemotherapy in advanced cancers while reducing costs by 95%.
- The Problem: Immunotherapies are very expensive, and most patients worldwide cannot access these treatments.
- The Hypothesis: The dose needed to saturate PD-1 receptors is much lower than the approved commercial dose.
- The Method: 500 patients with lung, head and neck, and other cancers were randomized: standard chemotherapy vs. ultra-low-dose nivolumab (20 mg every 2 weeks).
- The Result: Ultra-low-dose immunotherapy significantly prolonged overall survival (5.88 months vs. 4.70 months).
- Safety: Severe adverse effects were much less frequent in the immunotherapy arm (42.5% vs. 60.8%).
1. Scientific Rationale: Why a Low Dose?
The concept of the “Maximum Tolerated Dose (MTD)” that applies to chemotherapy in oncology may not be biologically applicable to immunotherapy. Immunotherapies target the immune system rather than the tumor directly.
Receptor Occupancy Theory
Phase I studies have shown that nivolumab doses as low as 0.1 mg/kg achieve PD-1 receptor occupancy on T cells of 60-70%. The standard approved dose (3 mg/kg or a fixed dose of 240 mg) is far above this biological requirement. While a blood drug concentration of 1.2 μg/mL is sufficient for efficacy, the standard dose raises this level to 33.7 μg/mL.
The Cost Gap (Financial Toxicity)
In countries such as India, where the study was conducted, and even in many Western countries, immunotherapies are prohibitively expensive.
91,328 TL / Dose
Monthly Cost: 182,656 TL
Unaffordable for most patients.
7,610 TL / Dose
90%+ Cost Savings
The possibility of access for a broader population.
2. DELII Study Protocol
This Phase III study, conducted at Tata Memorial Hospital, enrolled patients with relapsed/refractory solid tumors who had received at least one prior line of treatment.
Patient Profile
| Total Patients | 500 (250 Experimental Arm / 250 Control Arm) |
| Tumor Types | Head and Neck (52%), Lung-NSCLC (36%), Esophageal/Gastric (6%), Others (6%) |
| Previous Treatment | 29% of patients had received 2 or more prior lines of treatment. This was a heavily pretreated group. |
20 mg Fixed Dose
(IV every 2 weeks)
Docetaxel or Paclitaxel
(At the physician’s discretion)
3. Key Findings: Efficacy Analysis
Overall Survival (OS) - Primary Endpoint
Ultra-low-dose immunotherapy prolonged survival to a statistically significant extent compared with chemotherapy. The difference in survival at year 1 is particularly noteworthy.
Subgroup Analyses
The benefit was consistent across almost all subgroups. Regardless of age, sex, tumor type (lung or head and neck), or PD-L1 level, the low-dose immunotherapy arm appears advantageous or equivalent.
Interestingly, during the first 2-3 months, the survival curves were close together and could even appear to favor chemotherapy. After month 3, however, patients in the immunotherapy arm gained a clear advantage. This indicates that immunotherapy needs time for its effect to begin (“delayed effect”).
4. Safety and Quality of Life (QoL)
In the palliative (advanced disease) setting, how long a patient lives is as important as how they live. The DELII study provides clear data on this.
Adverse-Effect Profile
| Toxicity (Grade ≥3) | Chemotherapy Arm (%) | Low-Dose Nivolumab (%) | Comment |
|---|---|---|---|
| Overall Severe Adverse Effects | 60.8% | 42.5% | Immunotherapy is much safer. |
| Anemia | 21.5% | 7.8% | A clear difference. |
| Infections | 11.0% | 2.9% | Chemotherapy suppresses immunity. |
| Hyponatremia (Low Sodium) | 40.5% | 28.6% | High in both arms (regional factors may play a role). |
Quality-of-Life Data
In assessments using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires:
- General Health Status: Improvement or stability over time was observed in the immunotherapy arm.
- Head and Neck Cancer Symptoms: Difficulty swallowing, dry mouth, and speech problems were less frequent in the immunotherapy arm.
- Hair Loss (Alopecia): Although it was a substantial problem in those receiving chemotherapy, it was almost absent in the immunotherapy group.
Study Limitations
Like every scientific study, this one has limitations:
- Single Center: The study was conducted only at Tata Memorial Hospital in India. Larger multicenter studies are needed.
- No Standard-Dose Immunotherapy Arm: The study was designed as “Low Dose vs. Chemotherapy.” A “Low Dose vs. High Dose” comparison was not conducted because of cost.
- Brain Imaging: Because routine brain imaging was not performed, efficacy in patients with brain metastases is not fully clear.
A Step That Challenges Assumptions: “Less Is More”
For years, we have debated the high-dose standards set by the pharmaceutical industry. DELII provides some of the boldest and most concrete evidence on dose optimization in oncology. This study is vital both for India and for countries such as Turkey that must manage healthcare economics carefully.
Why Is It Important?
- Accessibility: Reducing a drug’s cost by 90% means increasing the number of patients who can access it 10-fold. This is an enormous public health gain.
- Toxicity Management: A lower dose means fewer adverse effects. Preserving our patients’ quality of life is as important as shrinking the tumor.
- Looking Ahead: The FDA’s “Project Optimus” initiative supports a similar philosophy: using drugs at the lowest effective dose possible. This study has become the strongest supporter of that movement.
In our clinical practice, particularly for patients who cannot access immunotherapy because of financial constraints, these data will allow us to consider low-dose protocols as an ethical and scientific option.
References
- Noronha V, Patil V, Menon N, et al. Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). Journal of Clinical Oncology. 2026. DOI: 10.1200/JCO-25-01546
- Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012.
- FDA Project Optimus: Reforming the Dose Optimization and Dose Selection Paradigm in Oncology.
- Patil V, et al. Low-dose immunotherapy in head and neck cancer: A randomized phase 3 trial. J Clin Oncol. 2023.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.